Alzinova Investor Relations Material
Latest events
Study Result
Alzinova
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Alzinova
Access all reports
Alzinova AB is a Swedish biotechnology company focused on developing treatments for Alzheimer's disease. The company's lead product is ALZ-101, a vaccine designed to target toxic oligomers of amyloid-beta, which are implicated in the progression of Alzheimer's. ALZ-101 has completed part A of its phase 1b clinical trial and continues to progress through clinical development. Alzinova is also working on ALZ-201, a monoclonal antibody that neutralizes these toxic oligomers, with a humanized version in early clinical trials. The company is headquartered in Mölndal, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
ALZ
Country
🇸🇪 Sweden